stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Book value per share
Cogent Biosciences, Inc.'s book value per share at the end of fiscal 2025 was 4.9×, up 100.1% from 2.5× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 3.1×. Over the past ten years it has ranged from −19.2× (fiscal 2017) to 21.2× (fiscal 2020); the current reading is higher than 73% of that period. Cogent Biosciences, Inc. ranks 215th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 4.9× | 100.06% |
| FY2024 | 2.5× | (23.75%) |
| FY2023 | 3.2× | (25.66%) |
| FY2022 | 4.4× | (21.27%) |
| FY2021 | 5.5× | (73.89%) |
| FY2020 | 21.2× | 408.07% |
| FY2019 | 4.2× | (56.93%) |
| FY2018 | 9.7× | — |
| FY2017 | −19.2× | — |
| FY2016 | −9.7× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 3.1× | (16.91%) |
| Mar 2026 | 3.7× | (24.11%) |
| Dec 2025 | 4.9× | 124.52% |
| Sep 2025 | 2.2× | 62.35% |
| 36 more quarters | Free account |
Against its own ten years
Low −19.2×
High 21.2×
Ten-year median
4.2×
Current reading's percentile
73
Book value per share against peers
| Company | Book value per share |
|---|---|
| DNTH Dianthus Therapeutics, Inc. compare | 21.6× |
| MANE Veradermics Incorporated compare | 20.1× |
| CRSP CRISPR Therapeutics AG compare | 17.0× |
| COGT Cogent Biosciences, Inc. | 3.1× |
| SRRK Scholar Rock Holding Corporation compare | 1.9× |
| ERAS Erasca, Inc. compare | 1.2× |
| KOD Kodiak Sciences Inc. compare | 1.0× |
| TVTX Travere Therapeutics, Inc. compare | 0.2× |
| PTCT PTC Therapeutics, Inc. compare | −2.3× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement